Breaking News, Promotions & Moves

CureVac Appoints Chief Development Officer

Dr. Edvardsen joins the company’s leadership team.

Author Image

By: Charlie Sternberg

Associate Editor

CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), has appointed Klaus Edvardsen, MD, PhD, as chief development officer. The appointment will take effect on August 1, 2021.   “We are very happy to welcome Dr. Edvardsen to the CureVac leadership team,” said Jean Stéphenne, chairman of the Supervisory Board of CureVac. “He has a tremendous background, having led both business development and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters